. Rates of morbidity and mortality have improved with better supportive measures and administration of HDC at an earlier phase in the course of the disease, but procedure-related mortality remains in the region of 10-20% in most published series using autologous bone marrow transplantation (ABMT) Jones et al, 1990; Reece et al, 1991; Bierman et al, 1993) . Approximately 50% of these fatalities will be as a consequence of idiopathic pneumonia syndrome (IPS). This presents with dyspnoea, pulmonary infiltrates and fever, and the differential diagnosis is between infection (often with an uncommon or unusual organism), pulmonary involvement with HD, intrapulmonary haemorrhage or druginduced pneumonitis (Clark et al, 1993) . The latter is most frequently associated with high-dose BCNU (carmustine), which induces interstitial fibrosis in a dose-dependent manner. (Litam et al, 1981; Pecego et al, 1986; Weaver et al, 1993) . The mechanism is poorly understood but thought to involve toxic metabolites that react with sulphydryl compounds (including glutathione) resulting in neutralization. Depletion of such compounds and inhibition of glutathione reductase in alveolar Received 19April 1995 Revised 11 October 1996 Accepted 14 October 1996 Correspondence to: D Cunningham macrophages is postulated to increase the risk of oxidant injury (Arrick et al, 1984; Clark et al, 1993) .
High-dose chemotherapy (HDC) with haematopoietic stem cell support is now employed in several clinical situations in the management of patients with Hodgkin's disease (HD) (Goldstone et al, 1993) . Rates of morbidity and mortality have improved with better supportive measures and administration of HDC at an earlier phase in the course of the disease, but procedure-related mortality remains in the region of 10-20% in most published series using autologous bone marrow transplantation (ABMT) Jones et al, 1990; Reece et al, 1991; Bierman et al, 1993) . Approximately 50% of these fatalities will be as a consequence of idiopathic pneumonia syndrome (IPS). This presents with dyspnoea, pulmonary infiltrates and fever, and the differential diagnosis is between infection (often with an uncommon or unusual organism), pulmonary involvement with HD, intrapulmonary haemorrhage or druginduced pneumonitis (Clark et al, 1993) . The latter is most frequently associated with high-dose BCNU (carmustine), which induces interstitial fibrosis in a dose-dependent manner. (Litam et al, 1981; Pecego et al, 1986; Weaver et al, 1993) . The mechanism is poorly understood but thought to involve toxic metabolites that react with sulphydryl compounds (including glutathione) resulting in neutralization. Depletion of such compounds and inhibition of glutathione reductase in alveolar macrophages is postulated to increase the risk of oxidant injury (Arrick et al, 1984; Clark et al, 1993) .
Pulmonary toxicity may occur 9 days to 12 years after starting BCNU (Durant et al, 1979) and may present with the sudden onset of dyspnoea and progress rapidly to death, or be more insidious with a fatal outcome within 2 years (Phillips et al, 1983) . In a dosefinding study published in 1990 using cyclophosphamide, etoposide and BCNU (Wheeler et al, 1990) 450 mg m-2 of BCNU was the maximum tolerated dose, with a 5% mortality rate compared with 22% observed following a dose of 600 mg ni-2. Another study using the same regimen and 600 mg m-2 BCNU, published the following year, reported a 16% incidence of IPS and a 12% mortality rate (Reece et al, 1991) . A more recent series (Weaver et al, 1993) reported no IPS in patients who received BCNU 300 mg m-2 a rate of 23% in patients who received 600 mg m-2.
The aim of our study was to quantify the risk and time of onset of IPS at our own institution and determine the risk factors for its development and prognostic factors for outcome. The indications for HDC and assessment criteria are as described previously (O'Brien et al, 1996) . Toxicity was graded according to the common toxicity criteria (National Cancer Institute, 1988 
PATIENTS AND METHODS

Using
Idiopathic pneumonia syndrome
At least one episode of IPS within the first year of HDC was observed in 26 patients (28%) with a median time of presentation of 91 days (range 12-336 days). Twenty-three out of twenty-six patients developed symptoms within the first 6 months. All patients presented with dyspnoea and/or cough and had pulmonary infiltrates or fibrosis on chest radiography. Pulmonary function tests and arterial blood gas estimations following HDC were abnormal in all cases tested. Bronchoscopy and bronchoalveolar lavage was performed in six patients. A total of 19 patients were treated with steroids, five of whom died compared with one fatality in the seven who did not receive steroids. Overall, 14 patients had complete resolution of symptoms and three had persisting symptoms at 6 months. The remaining nine patients died as a consequence of IPS at a median time from HDC of 74 days (range 19-418 days).
Of the nine patients who died, four had lung function tests performed before HDC and in three cases the result was normal. Four patients had lung or mediastinal disease at the time of HDC and one had previous lung disease. Two patients had previous mantle radiotherapy, five had previous bleomycin and one had both before HDC. All had dyspnoea (one patient grade II, five grade HI, three grade IV) and seven had a cough (six grade II, one grade III). All had British Journal of Cancer (1997) 75(7), 1044-1048 aPrevious lung diseases were recurrent chest infections (2), recurrent pneumothorax (1), pulmonary fibrosis (1), asthma (1) and idiopathic interstitial pneumonitits (1). pulmonary infiltration on chest radiography and all had their first episode of IPS within 6 months of HDC. Two patients had pulmonary function tests after high dose chemotherapy and both revealed grade IV toxicity. Arterial blood gas estimation was abnormal in all cases (toxicity: three grade H, two grade III and four grade IV). All patients were treated with antibiotics and mechanical ventilation and eight out of nine patients received steroids. The pathological diagnosis of interstitial pneumonitis was confirmed with open lung biopsy in one patient and at post-mortem in six. At the time of death, six patients were in remission and three had active Hodgkin's disease.
Prognostic factors
Univariate analysis of risk factors for developing IPS and prognostic factors for fatal outcome are shown in Table 2 . In terms of risk factors for developing pulmonary toxicity, the only two that reached conventional levels of statistical significance were female sex and dose of BCNU (P = 0.001 and 0.006 respectively). These were independently significant in the multivariate analysis (gender, P = 0.04; BCNU, as a continuous variable, P = 0.03). However, the increased risk with rising dose of BCNU appears to be confined to women (Table 3 and Figure 1 ). The hazard ratios for Previous studies have demonstrated an overall mortality associated with HDC for HD using ABMT of between 10% and 20% (Reece et al, 1991; Jones et al, 1990; Bierman et al, 1993; O'Brien et al, 1996) . The rates with individual regimens will depend on the doses and toxicities of the drugs in the conditioning therapy, as well as the amount of previous chemotherapy and irradiation and the number of patients in therapy-resistant relapse (Ahmed et al, 1990) . The type of haematopoietic support will also influence the risk as the period of neutropenia is less prolonged with PSCT and hence the frequency of infectious pulmonary complications would be reduced.
Drug-induced pneumonitis has been a well-recognised complication of treatment with BCNU since the 1970s (Collis et al, 1991) and the risk rises steadily with increasing dose (Aronin et al, 1980) . Other risk factors are pre-existing lung disease and smoking (Kreisman et al, 1992) , although the former just failed to reach statistical significance in the current study. In the light of the evidence that the incidence of IPS was reduced at lower doses of BCNU, the treatment policy at the RMH was changed in 1990 so that all doses of BCNU were < 500 mg m-2. Since that time, some pulmonary toxicity has been observed but there have been no fatal episodes of drug-induced pneumonitis, and our study confirms that increasing doses of BCNU are associated with a significantly higher risk for developing fatal lung toxicity (P = 0.001), with no deaths occurring in patients receiving < 475 mg m-2.
Female gender was a risk factor for both the development of IPS (P = 0.001) and for a fatal outcome (P = 0.01). The phenomenon of increased cardiopulmonary toxicity in women treated for HD has been noted previously, but the mechanism is obscure (Lund et al, 1996) . One assumes that drug handling and pharmacokinetics between the sexes may differ, but there is scant evidence for this supposition.
Patients who had received previous bleomycin or mantle radiotherapy did not have a higher risk of developing IPS in our study; this probably reflects the policy of adjusting the dose of BCNU in cases of abnormal lung function and omitting the drug altogether if the abnormality was severe. No adverse risk was associated with British Journal of Cancer (1997) 75(7), [1044] [1045] [1046] [1047] [1048] Idiopathic pneumonia syndrome after HDC 1047 increasing age (cut-off > 25 years), although the low numbers of patients of age > 50 years does not preclude this possibility, as suggested by prior studies (Miller et al, 1996) .
The predominant symptoms and signs associated with clinical BCNU-induced pulmonary toxicity were dyspnoea and dry hacking cough. Physical examination was non-specific and some patients had basal crepitations apparent on auscultation. When the patients presented with pulmonary symptoms the chest radiograph was abnormal in all cases. The main radiographic finding was bibasal interstitial infiltrates with a reticular-nodular pattern (75%); other signs detected were pulmonary fibrosis (25%), pleural effusion (19%) and pulmonary oedema (11%). These radiographic changes are similar to those in a previous report of chest radiograph abnormalities in patients with lymphoma following HDC and ABMT (Millard et al, 1991) . Pulmonary function studies generally showed varying restrictive defects and abnormality in the DLCO. This abnormality may precede radiographic changes and progress after discontinuing therapy. As BCNU can cause potentially lethal pulmonary toxicity if given inappropriately, pulmonary function tests should always be performed before the administration of this drug and used to calculate the correct dose. Once BCNU-related pulmonary toxicity occurs, the outcome is variable. The disease often progresses despite institution of intensive treatment with antibiotics, steroids and mechanical ventilation. In our study, the use of steroids was not controlled, but in general was given to those with the most severe symptoms and signs. This may well explain the higher fatality rate in those receiving steroids (five out of nineteen patients, 26%) compared to those who did not (one out of seven patients, 14%), although with such small numbers definitive conclusions are not possible.
The incidence of pulmonary toxicity in our study was 28% (26 out of 94 patients), and the mortality related to IPS was 35% (9 out of 26). Histological confirmation was obtained in seven of the nine patients who died (one at open lung biopsy and six at postmortem), with pathological features typical of cytotoxic injury.
We conclude that the main risk factors for IPS in HDC are dose of BCNU and female sex. Patients of either gender given less than 475 mg m-2 BCNU have a very low risk of developing fatal lung toxicity, and previous mantle radiotherapy and/or previous bleomycin do not appear to greatly increase this risk if lung function tests before HDC are within normal limits. A history of nonmalignant pulmonary disease probably increases the risk of IPS but not of a fatal outcome.
